Natural product-based anti-cancer agents: aza-Englerin analogues

The National Cancer Institute seeks partners interested in licensing or collaborative research to co-develop a treatment for Ewing ' s Sarcoma, with a goal of preclinical evaluation leading to clinical testing.IC: NCINIH Ref. No.: E-090-2014Advantages: Novel compounds with  potent and selective inhibitory effect on select cancer cells Parent compounds are effective inin vivo cancer models.Demonstrated bioavailability after oral administration (mouse model)Applications: Chemotherapeutic for renal cell carcinoma, in addition to glucose dependent tumors.  Treatment of diseases or conditions associated with insulin resistanceDevelopment Status: Pre-clinical (in vivo)Updated On: Dec 20, 2017Provider Classifications: Publications: Patent Application: 61/936,28562/018,381Licensing Contacts: Lead Inventor: Inventor IC: NCINCIUniv. of Hawaii-ManoaInventor Lab URL: https://ccr.cancer.gov/john-a-beutlerhttps://ccr.cancer.gov/william-douglas-figgInv Is lead: LPM Phone: [phone]LPM Email: [e-mail] Classification: TherapeuticsDTDT Description: TherapeuticsPat Filing Date: 2014-02-05T00:00:002014-06-27T00:00:00Publication Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=19061394http://www.ncbi.nlm.nih.gov/pubmed/?term=21476574http://www.ncbi.nlm.nih.gov/pubmed/?term=22280462http://www.ncbi.nlm.nih.gov/pubmed/?term=23352416Publication Caption: PMID 19061394PMID 2147657...

Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research